Sat Kartar Life Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/cl7t5jjuw517kkkt2wx7fm5x.pdf

Key Takeaways


Revenue Engine & Disruptions

Chadha: "Sat Kartar has still just learned to start walking. There's a long way to go."

Margin Trajectory & Profitability Drivers

Chadha: "I will not say 10%-11%, I will say, this jump is from 6%-9%. And yes, not only 6-9%, I will say 4%-6%, then 6-9%, then 12%-15%, and yes, 20% is also not far."

Hospital & Manufacturing Expansion


AI, Digital & Brand Building

Chadha: "Not really. Because this I have already anticipated into my business plan that yes, acquisition cost is going to be high. Google and Meta and other platforms are not going to spare any of the advertisers. They are first bothered about their pockets."

Customer Metrics & Definitions

Chadha: "The company is such a well-oiled machine, every system, is governing itself in such a way, that, if one name is removed, the company will not get a hit anywhere."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue targetINR 200+ crFY26
Revenue targetINR 300 crFY27 end
Revenue aspirationINR 500+ cr (product side only, excluding hospitals)FY28
PAT margin9% full-year (possible beat to 9-10%)FY26
PAT margin14-15%FY27
PAT margin exit rate18-20%FY28 exit
Hospital beds operationalFirst 30 bedsQ1 FY27
Hospital beds operationalFull 300 bedsQ4 FY27
Hospital breakeven6-8 months gestation per facilityFrom operational date
In-house capsule manufacturingAt least 50% of capsulesQ1 FY27 (possible)
Equity dilutionNone planned; entire hospital plan via internal accrualsOngoing
Quick-commerce testLiv Muztang on Blinkit in Maharashtra; cost/revenue analysisUnderway

Key Metrics

MetricQ2 FY26
Consolidated revenue₹91.9 cr, +18% YoY (H1 FY26)
Standalone revenue₹88.35 cr, +17% YoY (H1 FY26)
PAT margin8.81% (H1 FY26), up from 5% in H1 FY25
EBITDA margin improvement200+ bps YoY as a percentage of revenue (H1 FY26)
Top-line hit from May Indo-Pak disruption~₹6 cr
FY26 revenue target₹200+ cr
FY27 revenue target₹300 cr
FY28 revenue aspiration₹500 cr
FY27 PAT margin target12–15%
FY28 PAT margin target (exit run rate)18–20%
FY27 EBITDA margin guidance~15%
Average ticket size~₹3,300, up ~5% from ~₹3,000 earlier
Capsule and powder share of revenue50%
Own factory capacity utilization5–10% (started last month)
Hospital beds targeted by Q4 FY27300 beds
Hospital first phase30 beds by Q1 FY27, capex ~₹2 cr
Hospital revenue potential (300 beds, 90% utilization)~₹100 cr (per an analyst's math)
Hospital EBITDA margin target25–30%
Advertisement cost outlookflat to down 100–200 bps
Trade receivables recovery80% of stuck receivables received, rest in 10–15 days